Cardiol Therapeutics Stock Forecast, Price & News

Cardiol Therapeutics (NASDAQ:CRDL) Frequently Asked Questions

Is Cardiol Therapeutics a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cardiol Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Cardiol Therapeutics stock.
View analyst ratings for Cardiol Therapeutics or view top-rated stocks.

Are investors shorting Cardiol Therapeutics?

Cardiol Therapeutics saw a decline in short interest in January. As of January 15th, there was short interest totaling 173,700 shares, a decline of 27.2% from the December 31st total of 238,600 shares. Based on an average daily volume of 723,300 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.7% of the company's stock are sold short.
View Cardiol Therapeutics' Short Interest.

When is Cardiol Therapeutics' next earnings date?

Cardiol Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, February 21st 2022.
View our earnings forecast for Cardiol Therapeutics.

How were Cardiol Therapeutics' earnings last quarter?

Cardiol Therapeutics Inc (NASDAQ:CRDL) released its quarterly earnings data on Monday, November, 15th. The company reported ($0.18) earnings per share (EPS) for the quarter.
View Cardiol Therapeutics' earnings history.

What price target have analysts set for CRDL?

3 Wall Street analysts have issued twelve-month price targets for Cardiol Therapeutics' stock. Their forecasts range from $5.00 to $8.00. On average, they expect Cardiol Therapeutics' stock price to reach $6.50 in the next year. This suggests a possible upside of 269.3% from the stock's current price.
View analysts' price targets for Cardiol Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Cardiol Therapeutics' key executives?

Cardiol Therapeutics' management team includes the following people:

• David G. Elsley, President, Chief Executive Officer & Director
• Bernard Lim, Chief Operating Officer
• Christopher J. Waddick, Chief Financial Officer & Secretary
• Dan Crandall, Finance Director
• Anthony E. Bolton, Director of Research

Who are some of Cardiol Therapeutics' key competitors?

Some companies that are related to Cardiol Therapeutics include Valens (VLNS), Procaps Group S.A (PROC), Advantis (ADVT), Kaleido Biosciences (KLDO), RVL Pharmaceuticals (RVLP), High Tide (HITI), Novus Energy (NVS) and Takeda Pharmaceutical (TAK).
View all of CRDL's competitors.

What is Cardiol Therapeutics' stock symbol?

Cardiol Therapeutics trades on the NASDAQ under the ticker symbol "CRDL."

Who are Cardiol Therapeutics' major shareholders?

Cardiol Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Private Ocean LLC (0.05%) and Brookstone Capital Management (0.04%).

Which major investors are buying Cardiol Therapeutics stock?

CRDL stock was purchased by a variety of institutional investors in the last quarter, including Brookstone Capital Management, and Private Ocean LLC.

How do I buy shares of Cardiol Therapeutics?

Shares of CRDL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cardiol Therapeutics' stock price today?

One share of CRDL stock can currently be purchased for approximately $1.76.

How much money does Cardiol Therapeutics make?

Cardiol Therapeutics has a market capitalization of $78.50 million.

How can I contact Cardiol Therapeutics?

The company can be reached via phone at (289) 910-0850.